Material Agreements

American Drive Acquisition Co entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at $230,000,000 gross proceeds from sale of 23,000,000 units at $10 per unit (effective 2025-12-17).

“In connection with the IPO, the Company entered into the following agreements, forms of which were previously filed as exhibits to the Company’s Registration Statement: · An Underwriting Agreement, dated December 17, 2025, by and between the Company and Cantor Fitzgerald & Co., as representative of the several underwriters (the “ Representative ”), a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference.”

Launchpad Cadenza Acquisition Corp I entered into Private Placement Warrants Purchase Agreement with Cantor Fitzgerald & Co. (effective 2025-12-17).

“A Private Placement Warrants Purchase Agreement, dated December 17, 2025 (the " Cantor Private Placement Warrants Purchase Agreement "), by and between the Company and Cantor Fitzgerald & Co., a copy of which is attached as Exhibit 10.4 hereto and incorporated herein by reference.”

Launchpad Cadenza Acquisition Corp I entered into Private Placement Warrants Purchase Agreement with Launch Sponsor LLC (effective 2025-12-17).

“A Private Placement Warrants Purchase Agreement, dated December 17, 2025 (the " Sponsor Private Placement Warrants Purchase Agreement "), by and between the Company and Launch Sponsor LLC, a Delaware limited liability company (the " Sponsor "), a copy of which is attached as Exhibit 10.3 hereto and incorporated herein by reference.”

Launchpad Cadenza Acquisition Corp I entered into a underwriting with Cantor Fitzgerald & Co. (effective 2025-12-17).

“An Underwriting Agreement, dated December 17, 2025, by and between the Company and Cantor Fitzgerald & Co., as representative of the several underwriters (the " Representative "), a copy of which is attached as Exhibit 1.1 hereto and incorporated herein by reference.”

Distribution Solutions Group, Inc. amended Second Amended and Restated Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent valued at $400 million senior secured revolving credit facility (effective 2025-12-18).

“Second Amended and Restated Credit Agreement On December 18, 2025, Distribution Solutions Group, Inc. (the “ Company ”) and certain of its subsidiaries entered into the Second Amended and Restated Credit Agreement (the “ Amended and Restated Credit Agreement ”), which amended and restated that certain Amended and Restated Credit Agreement, dated as of April 1, 2022 (the “ Original Credit Agreement ”), by and among the Company, the other loan parties party thereto, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent.”

Emmaus Life Sciences, Inc. entered into Exchange Agreement and Exchange Note with a single individual valued at Issued 6,332,692 shares of common stock valued at approx. $0.38 per share and a convertible promisso (effective 2025-12-17).

“On December 17, 2025, Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" and the "company") entered into an Exchange Agreement dated as of the same day pursuant to which we agreed to issue to a single individual 6,332,692 shares of common stock of the company valued for this purpose at approximately $0.38 per share (the "Exchange Shares") and a convertible promissory note in the principal amount of $600,000 (the "Exchange Note" and together with the Exchange Shares, the "Exchange Securities") in exchange for the surrender for cancellation and satisfaction of the principal amount of an outstanding convertible promissory note currently due and payable in the principal amount of $3,000,000 (the "Subject Note")”

GeoVax Labs, Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC (effective 2025-12-19).

“On December 19, 2025, GeoVax Labs, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”)”

GeoVax Labs, Inc. entered into Purchase Agreement with the purchasers party thereto valued at aggregate of 13,244,896 common units (effective 2025-12-19).

“On December 19, 2025, GeoVax Labs, Inc. (the “Company”) entered into a placement agency agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (the “Placement Agent”) and a securities purchase agreement (the “Purchase Agreement”) with the purchasers party thereto, pursuant to which the Company agreed to issue and sell, in a public offering (the “Offering”), an aggregate of 13,244,896 common units”

STRATUS PROPERTIES INC entered into Agreement of Sale and Purchase with CH Realty X/R Houston Kingwood Place, L.P. valued at $60.8 million (effective 2025-12-18).

“On December 18, 2025 (the Effective Date), Stratus Kingwood Place, L.P. (Seller), a Texas limited partnership and a subsidiary of Stratus Properties Inc. (Stratus), entered into an Agreement of Sale and Purchase (the Purchase Agreement), with CH Realty X/R Houston Kingwood Place, L.P., a Delaware limited partnership (Purchaser), pursuant to which Seller agreed to sell to Purchaser the real and personal property associated with the Kingwood Place project for a purchase price of $60.8 million in cash.”

SITE Centers Corp. terminated Loan Agreement with Atlas SP Partners, L.P. and affiliates of Athene Annuity and Life Company valued at Repaid in full all amounts outstanding, principal approximately $64.0 million (effective 2025-12-18).

“On December 18, 2025, SITE Centers Corp. (the “Company”) repaid in full all amounts outstanding under the Loan Agreement, dated August 7, 2024 (the “Loan Agreement”), by and among certain subsidiaries of the Company and affiliates of Atlas SP Partners, L.P. and Athene Annuity and Life Company.”

3D SYSTEMS CORP amended Second Supplemental Indenture with Wilmington Savings Fund Society, FSB valued at Reduced minimum cash requirement from $40,000,000 to $20,000,000; deleted Restricted Cash Account co (effective 2025-12-22).

“On December 22, 2025, 3D Systems Corporation (the “Company”) entered into a second supplemental indenture (the “Second Supplemental Indenture”) to that certain indenture, dated as of June 23, 2025 (as previously supplemented, the “2030 Notes Indenture”), among the Company, the guarantors party thereto and Wilmington Savings Fund Society, FSB, as trustee and collateral agent.”

RENAISSANCERE HOLDINGS LTD amended Amendment with Citibank Europe Plc (effective 2025-12-22).

“Renaissance Reinsurance Ltd. (“RRL”), DaVinci Reinsurance Ltd. (“DaVinci”), RenaissanceRe Specialty U.S. Ltd. (“RSUSL”), and Renaissance Reinsurance of Europe Designated Activity Company (“ROE”) (each of RRL, DaVinci, RSUSL and ROE a “Company” and, collectively, the “Companies”) entered into a deed of amendment (the “Amendment”) to the existing secured letter of credit facility”

Simpson Manufacturing Co., Inc. entered into Second Amended and Restated Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and the other parties party thereto valued at 5-year revolving credit facility of $600,000,000, 5-year term loan facility of $300,000,000 (effective 2025-12-16).

“On December 16, 2025, Simpson Manufacturing Co., Inc. (the “Company”) entered into that certain Second Amended and Restated Credit Agreement (the “Second Amended and Restated Credit Agreement”), among the Company, the subsidiaries of the Company party thereto as guarantors, the lenders party thereto, Wells Fargo Bank, National Association (“Wells Fargo”), as administrative agent, and the other parties party thereto.”

Aspira Women's Health Inc. entered into Laboratory Services Agreement with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories (effective 2025-12-16).

“On December 16, 2025, Aspira Women’s Health Inc. (“Aspira”) entered into a Laboratory Services Agreement (the “Agreement”) with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories (“Mayo”).”

COTY INC. entered into Purchase and Sale Agreement with Tides Holdco Limited valued at $750,000,000 (effective 2025-12-18).

“On December 18, 2025, Coty JV Holding S.à r.l., a société à responsabilité limitée incorporated under the laws of Switzerland (“ Coty JV ”), an indirect subsidiary of Coty Inc. (the “ Company ”), entered into a Purchase and Sale Agreement (the “ Agreement ”) with Tides Holdco Limited”

BIOMARIN PHARMACEUTICAL INC entered into Agreement and Plan of Merger with Amicus Therapeutics, Inc. valued at $14.50 per Share in cash (effective 2025-12-19).

“On December 19, 2025, BioMarin Pharmaceutical Inc., a Delaware corporation (“ BioMarin ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Amicus Therapeutics, Inc. (the “ Company ” or “ Amicus ”), and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of BioMarin (“ Merger Sub ”), providing for the merger of Merger Sub with and into Amicus (the “ Merger ”), with Amicus surviving the Merger as a wholly owned subsidiary of BioMarin.”

USBC, Inc. amended Amended and Restated Digital Asset Management Agreement with Hyrcanian Asset Management, LLC valued at discretionary treasury management services with respect to the Company’s Bitcoin treasury strategy (effective 2025-12-12).

“On December 12, 2025, USBC, Inc. (the “Company”) entered into an Amended and Restated Digital Asset Management Agreement (the “Amended and Restated Agreement”) with Hyrcanian Asset Management, LLC (the “Manager”) to update and clarify the terms under which the Manager provides discretionary treasury management services with respect to the Company’s Bitcoin treasury strategy.”

XCel Brands, Inc. entered into Placement Agency Agreement with Wellington Shields & Co. LLC (effective 2025-12-17).

“Pursuant to the Placement Agency Agreement, dated December 17, 2025 (the “Placement Agency Agreement”), by and between the Company and Wellington Shields & Co. LLC (the “Placement Agent”), the Placement Agent served as the exclusive placement agent in connection with the Private Placement”

XCel Brands, Inc. entered into Securities Purchase Agreement with several institutional and accredited investors valued at $2.05 million (effective 2025-12-17).

“On December 17, 2025, Xcel Brands, Inc. (the “Company” or “Xcel”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with several institutional and accredited investors (the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of securities for gross proceeds at the Closing Date (as defined below) of $2.05 million.”

TXNM ENERGY INC amended Fifteenth Amendment to Credit Agreement with Wells Fargo Bank, National Association valued at $300.0 million (effective 2025-12-19).

“On December 19, 2025, TXNM entered into a Fifteenth Amendment to Credit Agreement (the “TXNM Revolver Amendment”) amending its $300.0 million revolving credit agreement (as amended, the “TXNM Revolver”), among TXNM, the lenders party thereto and Wells Fargo Bank, National Association (“Wells Fargo”), as administrative agent, which has an initial maturity date of March 30, 2029 with two extension options that each allow for an extension of the maturity for one additional year (the “TXNM Extension Options”).”

TXNM ENERGY INC entered into Twenty-Sixth Supplemental Indenture with U.S. Bank Trust Company, National Association valued at $70,000,000 aggregate principal amount of its 4.69% First Mortgage Bonds, due December 18, 2031, Ser (effective 2025-12-18).

“On December 18, 2025, TXNM Energy, Inc.’s (“TXNM”) indirect wholly-owned subsidiary, Texas-New Mexico Power Company (“TNMP”), issued $70,000,000 aggregate principal amount of its 4.69% First Mortgage Bonds, due December 18, 2031, Series 2025H (the “2025H Bonds”) in a private placement in reliance on an exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”).”

GALECTIN THERAPEUTICS INC entered into December 2025 Supplemental Line of Credit Agreement with Richard E. Uihlein valued at up to $10.00 million line of credit (effective 2025-12-19).

“On December 19, 2025, Galectin Therapeutics Inc. (the “Company”) and Richard E. Uihlein (the “Lender”) entered into a Line of Credit Letter Agreement (the “December 2025 Supplemental Line of Credit Agreement”), pursuant to which the Lender shall provide the Company a line of credit of up to $10.00 million (the “Line of Credit”) to finance the Company’s working capital needs.”

AMICUS THERAPEUTICS, INC. entered into Agreement and Plan of Merger with BioMarin Pharmaceutical Inc. valued at $14.50 per Share in cash (effective 2025-12-19).

“On December 19, 2025, Amicus Therapeutics, Inc. (the “ Company ” or “ Amicus ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with BioMarin Pharmaceutical Inc., a Delaware corporation (“ Parent ”), and Lynx Merger Sub 1, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“ Merger Sub ”), providing for the merger of Merger Sub with and into the Company (the “ Merger ”),”

YELP INC amended First Amendment to Revolving Credit and Guaranty Agreement with JPMorgan Chase Bank, N.A., Wells Fargo Bank, National Association valued at $325.0 million (effective 2025-12-18).

“On December 18, 2025, Yelp Inc. (the “Company”) entered into the First Amendment to Revolving Credit and Guaranty Agreement (the “Amendment”) with the lenders party thereto, JPMorgan Chase Bank, N.A., as the existing administrative agent and collateral agent, and Wells Fargo Bank, National Association, as the successor administrative agent and collateral agent, which amended the Company’s Revolving Credit and Guaranty Agreement, dated as of April 28, 2023 (the “Credit Agreement”).”

Compass Group Diversified Holdings LLC amended Fifth Amendment Transaction Letter with Bank of America, N.A. valued at milestone fees in the amount of $5,000,000, $6,500,000, $8,000,000 and $9,500,000 (effective 2025-12-19).

“On December 19, 2025, Compass Group Diversified Holdings LLC (the “ Company ”) entered into a Fifth Amendment to Credit Agreement and Limited Waiver Agreement (the “ Fifth Amendment ”) and a Fifth Amendment Transaction Letter (the “ Transaction Letter ”), each with Bank of America, N.A. (the “ Administrative Agent ”), in its capacity as administrative agent for the lenders, swing line lender, and L/C issuer under that certain Third Amended and Restated Credit Agreement, dated as of July 12, 2022 (as amended, modified, extended, restated, replaced, or supplemented in writing from time to time, the “ Credit Agreement ”), and the lenders party to the Credit Agreement representing at least 50% of the total credit exposure of all lenders under the Credit Agreement (the “ Consenting Lenders ”).”

Compass Group Diversified Holdings LLC amended Fifth Amendment to Credit Agreement and Limited Waiver Agreement with Bank of America, N.A. valued at aggregate revolving commitments under the Credit Agreement will revert back to $100,000,000 (effective 2025-12-19).

“On December 19, 2025, Compass Group Diversified Holdings LLC (the “ Company ”) entered into a Fifth Amendment to Credit Agreement and Limited Waiver Agreement (the “ Fifth Amendment ”) and a Fifth Amendment Transaction Letter (the “ Transaction Letter ”), each with Bank of America, N.A. (the “ Administrative Agent ”), in its capacity as administrative agent for the lenders, swing line lender, and L/C issuer under that certain Third Amended and Restated Credit Agreement, dated as of July 12, 2022 (as amended, modified, extended, restated, replaced, or supplemented in writing from time to time, the “ Credit Agreement ”), and the lenders party to the Credit Agreement representing at least 50% of the total credit exposure of all lenders under the Credit Agreement (the “ Consenting Lenders ”).”

Keurig Dr Pepper Inc. amended Amendment No. 1 to Bridge Credit Agreement with Morgan Stanley Senior Funding, Inc. (MSSF) valued at €10.35 billion reduction to €5.85 billion (effective 2025-12-18).

“On December 18, 2025, the Company entered into an amendment (the “ Amendment No. 1 ”) to its Bridge Credit Agreement, dated August 24, 2025 (the “ Bridge Credit Agreement ”), with the lenders party thereto and MSSF, as administrative agent. Pursuant to the Amendment No. 1, lenders’ commitment to provide KDP with financing under a 364-day senior unsecured bridge loan facility was reduced by €10.35 billion, from €16.2 billion to €5.85 billion.”

Keurig Dr Pepper Inc. entered into Term Loan Agreement with Morgan Stanley Senior Funding, Inc. (MSSF) valued at €10.35 billion (effective 2025-12-18).

“On December 18, 2025, Keurig Dr Pepper Inc. (“ KDP ” or the “ Company ”) entered into a Term Loan Agreement (the “ Term Loan Agreement ”), with the lenders party thereto and Morgan Stanley Senior Funding, Inc. (“ MSSF ”), as administrative agent, pursuant to which each lender has committed, subject to satisfaction of certain conditions set forth in the Term Loan Agreement, to provide KDP with financing under a 364-day term loan facility in an aggregate amount not to exceed €10.35 billion.”

Marvion Inc. entered into Stock Purchase Agreement with Mak Pak Fai Ray valued at Two Hundred Thousand Dollars ($200,000) (effective 2025-12-16).

“On December 16, 2025, Marvion Inc. (the “Company”) and Mak Pak Fai Ray (the “Investor”) entered into a Stock Purchase Agreement (the “Agreement”) pursuant to which the Investor shall purchase from the Company at Two Hundred Thousand Dollars ($200,000) of the Company’s Common Stock”

abrdn Income Credit Strategies Fund entered into Securities Purchase Agreement with each purchaser named therein valued at 4,000,000 Series A Mandatorily Redeemable Preferred Shares due December 18, 2030, liquidation prefer (effective 2025-12-18).

“On December 18, 2025, abrdn Income Credit Strategies Fund (NYSE: ACP) (the “Fund”) entered into a securities purchase agreement (the “Purchase Agreement”), by and among the Fund and each purchaser named therein (the “Purchasers”), in connection with the issuance and sale of 4,000,000 shares of the Fund’s Series A Mandatorily Redeemable Preferred Shares due December 18, 2030, liquidation preference of $25.00 (the “MRP Shares”), in a transaction exempt from registration pursuant to Rule 506(c) under the Securities Act of 1933, as amended (the “Preferred Placement”).”

Ares Commercial Real Estate Corp amended Third Amended and Restated Master Repurchase and Securities Contract with Wells Fargo Bank, National Association valued at from $450.0 million to $600.0 million (effective 2025-12-18).

“ACRC Lender W LLC, ACRC Lender W TRS LLC, ACRC Warehouse Holdings LLC and ACRC 2017-FL3 Holder REIT LLC, each a subsidiary of Ares Commercial Real Estate Corporation (the “Company”), and the Company entered into an amendment to the Third Amended and Restated Master Repurchase and Securities Contract with Wells Fargo Bank, National Association”

Streamex Corp. entered into Second Convertible Debenture (second tranche) with YA II PN, LTD. valued at Issuance of second tranche convertible debenture with principal amount of $25,000,000; conversion pr (effective 2025-12-17).

“greement with YA II PN, LTD., a Cayman Islands exempt limited company (“Yorkville” or the “Investor”), for the issuance and sale by the Company of convertible debentures (the “Convertible Debentures,” each, a “Convertible Debenture”), which Convertible Debentures will be convertible into shares of the”

Streamex Corp. amended Secured Convertible Debenture Purchase Agreement Amendment No. 4 with YA II PN, LTD. valued at Amendment to Secured Convertible Debenture Purchase Agreement; $25,000,000 second tranche convertibl (effective 2025-12-17).

“Further to this, on December 17, 2025, the Company entered into a certain Amendment No. 4 to the Debenture Purchase Agreement (the “Fourth Amendment”) with Yorkville.”

ArrowMark Financial Corp. entered into Securities Purchase Agreement with certain investors named therein (effective 2025-12-18).

“On December 18, 2025, ArrowMark Financial Corp. (NASDAQ: BANX) (the “Company”), a closed-end investment company, entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors named therein (the “Investors”), relating to a direct public offering (the “Offering”) of 673,249 shares of the Company’s common stock (“Common Stock”).”

Rocky Mountain Chocolate Factory, Inc. amended Amendment to Letter Agreement with Global Value Investment Corporation valued at GVIC ownership limit set at 25.0% of Voting Securities (effective 2025-12-18).

“In connection with the Transaction, the Company and the other parties thereto entered into an amendment (the “Amendment”) to the letter agreement, dated November 26, 2024 (the “Letter Agreement”), between the Company, Global Value Investment Corporation and certain of its affiliates (collectively “GVIC”) and certain other parties.”

Rocky Mountain Chocolate Factory, Inc. entered into Investor Rights Agreement with ARM-D Rocky Mountain Chocolate Holdings LLC valued at Registration rights, preemptive rights, board designation right, standstill provisions (effective 2025-12-18).

“In connection with the Purchase Agreement, the Company entered into an investor rights agreement with the Purchaser, dated December 18, 2025 (the “Investor Rights Agreement”), pursuant to which the Purchaser is, among other things, entitled to certain resale registration rights with respect to shares of the Company’s common stock issued to the Purchaser.”

Rocky Mountain Chocolate Factory, Inc. entered into Securities Purchase Agreement with ARM-D Rocky Mountain Chocolate Holdings LLC valued at 1,500,000 shares of common stock at $1.80 per share, total proceeds $2.7 million (effective 2025-12-18).

“On December 18, 2025, Rocky Mountain Chocolate Factory, Inc. (the “Company”) completed the private placement of an aggregate of 1,500,000 of shares of the Company’s common stock at a price per share equal to $1.80 (the “Transaction”) to ARM-D Rocky Mountain Chocolate Holdings LLC (the “Purchaser”) pursuant to a securities purchase agreement (the “Purchase Agreement”).”

Profound Medical Corp. entered into Placement Agent Agreement with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC valued at cash fee of 5.0% of gross proceeds from the sale of Shares plus reimbursement of documented out-of-p (effective 2025-12-19).

“On December 19, 2025, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC (“Konik Capital Partners”) pursuant to which the Company engaged Konik Capital Partners as the placement agent (the “Placement Agent”) in connection with the Offering.”

Profound Medical Corp. entered into Securities Purchase Agreement with certain investors (the Purchasers) valued at aggregate of 5,142,870 common shares at $7.00 per share for aggregate gross proceeds of $36 million (effective 2025-12-19).

“On December 19, 2025, Profound Medical Corp. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (collectively, the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a registered direct offering (the “Offering”) an aggregate of 5,142,870 shares (the “Shares”) of the Company’s common shares (the “Common Shares”), at a price of $7.00 per share, for aggregate gross proceeds to the Company of $36 million before deducting the placement agent’s fees and related offering expenses.”

Audax Credit BDC Inc. entered into Subscription Agreement with Mercer Audax Credit Feeder Fund LP valued at $15,000,000 capital commitment (effective 2025-12-16).

“Effective December 16, 2025, Audax Credit BDC Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with Mercer Audax Credit Feeder Fund LP, the Company’s controlling shareholder (the “Investor”), pursuant to which the Investor has made a capital commitment in respect of the Company’s common stock, par value $0.001 per share (the “Common Stock”), in an amount equal to $15.0 million.”

Cue Biopharma, Inc. entered into Underwriting Agreement with H.C. Wainwright & Co., LLC (effective 2025-12-19).

“On December 19, 2025, Cue Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC, as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering”

BeOne Medicines Ltd. terminated CMB Credit Facility with China Merchants Bank Co., Ltd. valued at Repaid in full all outstanding amounts, terminated all commitments and guarantees, no termination pe (effective 2025-12-16).

“On December 16, 2025, the Company utilized a portion of the proceeds from borrowings under the Facilities Agreement to repay in full all outstanding amounts owed under the Company’s Facility Agreement, dated as of December 9, 2024, by and between the Company and China Merchants Bank Co., Ltd. (the “CMB Credit Facility”), and terminated all commitments by the lender to extend further credit under the CMB Credit Facility and all guarantees and security interests granted by the Company to the lender under the CMB Credit Facility.”

Cottonwood Communities, Inc. amended Amendment with CC Advisors III, LLC (effective 2025-12-18).

“On December 18, 2025, Cottonwood Communities, Inc. (“CCI”), Cottonwood Residential O.P., LP (“CROP”), a subsidiary and the operating partnership of CCI, and CC Advisors III, LLC (“CC Advisors III”), the external advisor to CCI and CROP, entered into an amendment (the “Amendment”) to the Amended and Restated Advisory Agreement dated May 7, 2025 (the “Advisory Agreement”).”

Inmune Bio, Inc. entered into Sales Agreement with A.G.P./Alliance Global Partners valued at up to $65,000,000 (effective 2025-12-19).

“On December 19, 2025, INmune Bio Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), as sales agent, pursuant to which the Company may offer and sell, from time to time, through A.G.P., up to $65,000,000 of shares of its common stock”

BrightSpire Capital, Inc. amended Seventh Amendment to WLS Repurchase Agreement with Wells Fargo Bank, National Association valued at $500.0 million (effective 2025-12-16).

“On December 16, 2025, WLS Seller and Wells entered into an Amendment No. 7 to the WLS Repurchase Agreement (the “Seventh Amendment to WLS Repurchase Agreement”) and Fifth Amendment to Guarantee Agreement (the “Fifth WLS Guarantee Agreement”), under which Wells agreed that the required minimum consolidated tangible net worth of the Guarantor is reduced from $1.11 billion to $900 million, and to increase the facility size from $400.0 million to $500.0 million (with maximum upsize options to $600.0 million, subject to Wells approval).”

BrightSpire Capital, Inc. entered into Master Repurchase and Securities Contract with Wells Fargo Bank, National Association valued at up to $300.0 million (effective 2018-11-02).

“On November 2, 2018, CLNC Credit 8, LLC, now known as BrightSpire Credit 8, LLC (“WLS Seller”), an indirect subsidiary of BrightSpire Capital, Inc. (the “Company”), entered into a Master Repurchase and Securities Contract (the “WLS Repurchase Agreement”) with Wells Fargo Bank, National Association (“Wells”).”

IN8BIO, INC. entered into Securities Purchase Agreement with the purchasers named therein (the "Investors") valued at aggregate gross proceeds of approximately $20.1 million (effective 2025-12-18).

“On December 18, 2025, IN8bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”)”

Mirum Pharmaceuticals, Inc. entered into Subscription Agreement with entities associated with TCG Crossover Management, LLC valued at approximately $68,480,000 (effective 2025-12-18).

“On December 18, 2025, Mirum Pharmaceuticals, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with entities associated with TCG Crossover Management, LLC (“TCGX”), an institutional investor (the “PIPE Investors”), pursuant to which the PIPE Investors have agreed, subject to the terms and conditions of the Subscription Agreement, to purchase immediately following the Closing (as defined below), 1,000,000 shares (the “PIPE Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), for an aggregate gross purchase price of approximately $68,480,000 (the “Private Placement”).”

Tectonic Financial, Inc. entered into Separation Agreement and Plan of Distribution with Tectonic Advisors, LLC, certain equity owners of Cain Watters & Associates, LLC, and Cain Watters & Associates, LLC (effective 2025-12-19).

“On December 19, 2025, Tectonic Financial, Inc. (the “Company”) entered into a Separation Agreement and Plan of Distribution (the “Separation Agreement”) with Tectonic Advisors, LLC, a Texas limited liability company and wholly owned subsidiary of the Company (“Spinco”), and certain equity owners (the “TA Continuing Shareholders”) of Cain Watters & Associates, LLC (“Cain Watters”).”

Cannabist Co Holdings Inc. entered into Equity Purchase Agreement with Parma Holdco LLC valued at Total consideration of $130 million ($117.5 million payable at closing and $12.5 million in escrow) (effective 2025-12-18).

“On December 18, 2025, The Cannabist Company Holdings Inc. (the “Company”), Green Leaf Medical of Virginia, LLC, a subsidiary of the Company (“Green Leaf Virginia”), and Green Leaf Medical, LLC, another subsidiary of the Company and the sole member of Green Leaf Virginia (the “Member”), entered into an equity purchase agreement (the “Equity Purchase Agreement” and the transaction contemplated thereunder, the “Transaction”) with Parma Holdco LLC (“Buyer”) and, solely for the limited purposes set forth therein, Millstreet Credit Fund LP (“Millstreet”).”